Journal article 752 views
Use, patient selection and outcomes of P2Y12 receptor inhibitors in patients with STEMI based on contemporary European registries.
Nicholas Danchin,
Maddalena Lettina,
Uwe Zeymer,
Petr Widimsky,
Alfredo Bardaji,
Jose Barrabes,
Angel Cequier,
Marc Claeys,
Leonardo De Luca,
Jakob Dörler,
David Erlinge,
Paul Erne,
Patrick Goldstein,
Sasha Koul,
Gilles Lemesle,
Thomas Lüscher,
Christian Matter,
Gilles Montalescot,
Dragana Radovanovic,
Jose Lopez Sendón,
Petr Tousek,
Franz Weidinger,
Clive Weston 
,
Azfar Zaman,
Pontus Andell,
Jin Li,
Wouter Jukema
,
Azfar Zaman,
Pontus Andell,
Jin Li,
Wouter Jukema
European Heart Journal - Cardiovascular Pharmacotherapy
Swansea University Author:
Clive Weston
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1093/ehjcvp/pvw003
Abstract
Aims To describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries.Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also prov...
| Published in: | European Heart Journal - Cardiovascular Pharmacotherapy |
|---|---|
| Published: |
2016
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa26696 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
Aims To describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries.Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registries were heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09–3.55% in-hospital (8 registries), 0.09–1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry). |
|---|---|
| Keywords: |
Effectiveness; Safety; Acute coronary syndromes; ST-segment elevation myocardial infarction |
| College: |
Faculty of Medicine, Health and Life Sciences |